Centre for Commercialization of Regenerative Medicine (CCRM)
The Centre for Commercialization of Regenerative Medicine (CCRM) provides innovative contract development and manufacturing organization (CDMO) services to enable the development and commercialization of cell and gene therapies and regenerative medicine-based technologies. With its customer-focused approach customized to each client, CCRM provides process development and current Good Manufacturing Practices (cGMP) manufacturing services tailored to its clients’ timelines, financing, ambitions and needs.
Location
MaRS Centre, West Tower
661 University Avenue – Suite 1002
Toronto, Ontario
M5G 1M1
Areas of Expertise
Good Manufacturing Practices (GMP), induced pluripotent stem cell (iPSC) reprogramming, gene editing, and differentiation
Automated, closed, integrated, process development (PD) and manufacturing for T-cells and natural killer (NK) cells
Viral vector (lentivirus, adeno-associated virus, other) upstream and downstream process development and optimization for manufacturing
GMP-compliant manufacturing of master/working cell banks
Analytical development including high-throughput screening assays, quality control (QC) testing, and ICH stability studies
Assessment of next-generation bioprocessing hardware and technologies
Services
Process R&D
Product R&D
Business Development & Consulting
Contact Information
Website: https://www.ccrm.ca/
Email: cdmo@ccrm.ca
Twitter: @CCRM_ca
LinkedIn: CCRM
Published: September 14, 2021